Immune Design Stock Price, News & Analysis (NASDAQ:IMDZ)

$3.75 0.05 (1.35 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$3.70
Today's Range$3.65 - $3.82
52-Week Range$3.55 - $13.05
Volume745,322 shs
Average Volume315,390 shs
Market Capitalization$189.83 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

About Immune Design (NASDAQ:IMDZ)

Immune Design logoImmune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Receive IMDZ News and Ratings via Email

Sign-up to receive the latest news and ratings for IMDZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMDZ
CUSIPN/A
Phone206-682-0645

Debt

Debt-to-Equity RatioN/A
Current Ratio5.00%
Quick Ratio4.96%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.26 million
Price / Sales13.59
Cash FlowN/A
Price / CashN/A
Book Value$3.75 per share
Price / Book1.00

Profitability

Trailing EPS($2.13)
Net Income$-53,530,000.00
Net Margins-619.62%
Return on Equity-68.69%
Return on Assets-56.69%

Miscellaneous

Employees51
Outstanding Shares48,060,000

Immune Design (NASDAQ:IMDZ) Frequently Asked Questions

What is Immune Design's stock symbol?

Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."

How were Immune Design's earnings last quarter?

Immune Design Corp (NASDAQ:IMDZ) posted its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.11. The biotechnology company earned $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. View Immune Design's Earnings History.

When will Immune Design make its next earnings announcement?

Immune Design is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Immune Design.

Where is Immune Design's stock going? Where will Immune Design's stock price be in 2017?

4 brokerages have issued 1 year price targets for Immune Design's stock. Their forecasts range from $10.00 to $20.00. On average, they anticipate Immune Design's share price to reach $16.00 in the next year. View Analyst Ratings for Immune Design.

What are Wall Street analysts saying about Immune Design stock?

Here are some recent quotes from research analysts about Immune Design stock:

  • 1. According to Zacks Investment Research, "Immune Design reported narrower than expected loss in the third quarter of 2017. Currently, the company’s primary candidate, CMB305 is being evaluated for soft tissue sarcoma and G100 for Merkel cell carcinoma, follicular non-Hodgkin Lymphoma and sarcoma. Further, it had productive discussion with the FDA regarding CMB305 and has planned to initiate a pivotal phase III trial evaluating CMB305 as monotherapy in synovial sarcoma patients by mid 2018. The company is working towards the potential registration paths of these products. We are positive on its strategic agreements with companies like Sanofi, Roche, and Merck, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. Although such collaborations boost its pipeline development, dependence on other companies for revenue growth increases vulnerability too." (11/10/2017)
  • 2. Jefferies Group LLC analysts commented, "Though 2016 was relatively quiet, we believe the year of trial execution helped establish a foundation to build upon in 2017, with accumulating CMB305/ LV305 OS data and randomized '305 and '100 datasets potentially helping confirm the agents' promise and potential regulatory path. With data at AACR, ASCO, ESMO, and ASH this year, we see catalysts to draw greater attention to IMDZ and drive upside for shares; increasing tgt to $16. Financials: 4Q OpEx was $16.6M, consisting of $12.0M R&D vs. our $11.6M est and $4.4M G&A, vs. our $4.2M est. Their net loss was $14.5M compared to our $13.8M est. The company ended the quarter with $110.4M in cash, which includes $30.3M from follow-on financing. IMDZ believes their cash position should provide a runway until 2H18. Updated follow-up data for CMB305 and LV305 in soft tissue sarcoma (STS) suggests survival tracking well ahead of historical data." (3/8/2017)

Are investors shorting Immune Design?

Immune Design saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,348,299 shares, an increase of 86.6% from the October 31st total of 722,704 shares. Based on an average trading volume of 1,177,872 shares, the days-to-cover ratio is presently 1.1 days. Currently, 5.2% of the shares of the company are short sold.

Who are some of Immune Design's key competitors?

Who are Immune Design's key executives?

Immune Design's management team includes the folowing people:

  • Edward E. Penhoet Ph., D., Independent Chairman of the Board (Age 77)
  • Carlos V. Paya M.D., Ph.D., President, Chief Executive Officer, Director (Age 58)
  • Stephen R. Brady J.D., Executive Vice President, Strategy & Finance (Age 47)
  • Sergey Yurasov M.D., Ph.D., Senior Vice President, Clinical Development, and Chief Medical Officer (Age 48)
  • Jan Henrik Ter Meule M.D., Chief Scientific Officer (Age 54)
  • Melanie Morrison, Vice President - Oncology Platform Leader
  • Heidi Petersen, Vice President - Regulatory Affairs
  • Wayne R. Gombotz Ph.D., Chief Development Officer (Age 57)
  • David Baltimore Ph.D., Independent Director (Age 79)
  • Franklin M. Berger, Independent Director (Age 67)

Who owns Immune Design stock?

Immune Design's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include COLUMN GROUP L P (5.90%), ECOR1 CAPITAL, LLC Total Shares: 3,562,600 (7.40%), Victory Capital Management Inc. (8.04%), JPMorgan Chase & Co. (1.97%), Wells Fargo & Company MN (0.68%) and EAM Investors LLC (0.15%). Company insiders that own Immune Design stock include Carlos V Paya, Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Peter Svennilson, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design.

Who sold Immune Design stock? Who is selling Immune Design stock?

Immune Design's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, JPMorgan Chase & Co., Trexquant Investment LP and OxFORD Asset Management LLP. Company insiders that have sold Immune Design company stock in the last year include Carlos V Paya, Franklin M Berger, Lewis W Coleman, Stephen R Brady and Wayne Gombotz. View Insider Buying and Selling for Immune Design.

Who bought Immune Design stock? Who is buying Immune Design stock?

Immune Design's stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., EAM Investors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Immune Design stock in the last two years include Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Peter Svennilson and Stephen R Brady. View Insider Buying and Selling for Immune Design.

How do I buy Immune Design stock?

Shares of Immune Design can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Design's stock price today?

One share of Immune Design stock can currently be purchased for approximately $3.75.

How big of a company is Immune Design?

Immune Design has a market capitalization of $189.83 million and generates $13.26 million in revenue each year. The biotechnology company earns $-53,530,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Immune Design employs 51 workers across the globe.

How can I contact Immune Design?

Immune Design's mailing address is 1616 EASTLAKE AVE. E SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]


MarketBeat Community Rating for Immune Design (IMDZ)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immune Design (NASDAQ:IMDZ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.803.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$18.00$18.00
Price Target Upside: 332.43% upside58.42% upside92.51% upside170.68% upside

Immune Design (NASDAQ:IMDZ) Consensus Price Target History

Price Target History for Immune Design (NASDAQ:IMDZ)

Immune Design (NASDAQ:IMDZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017CowenReiterated RatingBuyLowView Rating Details
10/17/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$29.00 -> $10.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
6/28/2017Jefferies GroupReiterated RatingBuy$18.00MediumView Rating Details
6/10/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Immune Design (NASDAQ:IMDZ) Earnings History and Estimates Chart

Earnings by Quarter for Immune Design (NASDAQ:IMDZ)

Immune Design (NASDAQ IMDZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018        
11/1/2017Q3 2017($0.63)($0.52)$0.62 million$0.52 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.65)($0.54)$1.50 million$0.73 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.57)($0.57)$1.34 million$2.06 millionViewListenView Earnings Details
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
8/9/2016Q2($0.68)($0.71)$1.50 million$1.13 millionViewN/AView Earnings Details
5/10/2016Q1($0.62)($0.61)$0.85 million$1.86 millionViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.40 million$1.78 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015Q4 2014($0.68)($0.78)$0.78 million$1.80 millionViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)$0.20 million$3.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Immune Design (NASDAQ:IMDZ) Earnings Estimates

2017 EPS Consensus Estimate: ($2.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.61)($0.55)($0.58)
Q2 20172($0.65)($0.60)($0.63)
Q3 20172($0.74)($0.64)($0.69)
Q4 20172($0.42)($0.34)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Design (NASDAQ:IMDZ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Immune Design (NASDAQ IMDZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.70%
Institutional Ownership Percentage: 29.38%
Insider Trades by Quarter for Immune Design (NASDAQ:IMDZ)
Institutional Ownership by Quarter for Immune Design (NASDAQ:IMDZ)

Immune Design (NASDAQ IMDZ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/2/2017Lewis W ColemanDirectorBuy50,000$4.50$225,000.00View SEC Filing  
10/30/2017Franklin M BergerDirectorBuy25,000$4.58$114,500.00View SEC Filing  
10/27/2017Leo GuthartMajor ShareholderBuy2,439,000$4.10$9,999,900.00View SEC Filing  
10/27/2017Peter SvennilsonDirectorBuy2,681,000$4.10$10,992,100.00View SEC Filing  
10/25/2017Franklin M BergerDirectorBuy25,000$4.26$106,500.00View SEC Filing  
10/24/2017Leo GuthartMajor ShareholderBuy60,000$4.65$279,000.00View SEC Filing  
10/19/2017Leo GuthartMajor ShareholderBuy10,000$6.09$60,900.00View SEC Filing  
9/18/2017Leo GuthartMajor ShareholderBuy10,000$9.70$97,000.00View SEC Filing  
8/1/2017Wayne GombotzInsiderSell10,000$11.43$114,300.00View SEC Filing  
7/11/2017Lewis W ColemanDirectorBuy12,000$9.05$108,600.00View SEC Filing  
7/10/2017Lewis W ColemanDirectorBuy10,000$9.00$90,000.00View SEC Filing  
7/7/2017Lewis W ColemanDirectorBuy8,000$9.27$74,160.00View SEC Filing  
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.00View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.70View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.00View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.00View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.00View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immune Design (NASDAQ IMDZ) News Headlines

Source:
DateHeadline
Immune Design (IMDZ) Earns Buy Rating from CowenImmune Design (IMDZ) Earns Buy Rating from Cowen
www.americanbankingnews.com - December 12 at 1:42 PM
Immune Design Corp (IMDZ) Expected to Post Earnings of -$0.39 Per ShareImmune Design Corp (IMDZ) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - November 30 at 3:10 AM
Short Interest in Immune Design Corp (IMDZ) Expands By 86.6%Short Interest in Immune Design Corp (IMDZ) Expands By 86.6%
www.americanbankingnews.com - November 29 at 2:38 AM
Immune Design Corp (IMDZ) Given Consensus Recommendation of "Hold" by BrokeragesImmune Design Corp (IMDZ) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 28 at 1:36 AM
ETFs with exposure to Immune Design Corp. : November 24, 2017ETFs with exposure to Immune Design Corp. : November 24, 2017
finance.yahoo.com - November 24 at 4:57 PM
Commit To Purchase Immune Design Corp At $2.50, Earn 10.3% Annualized Using Options - TheStreet.comCommit To Purchase Immune Design Corp At $2.50, Earn 10.3% Annualized Using Options - TheStreet.com
www.thestreet.com - November 17 at 6:50 AM
Immune Design to Present at Jefferies 2017 London Healthcare ConferenceImmune Design to Present at Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 13 at 7:53 PM
ETFs with exposure to Immune Design Corp. : November 13, 2017ETFs with exposure to Immune Design Corp. : November 13, 2017
finance.yahoo.com - November 13 at 7:53 PM
Immune Design Corp. (IMDZ) Expected to Post Quarterly Sales of $810,000.00Immune Design Corp. (IMDZ) Expected to Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - November 13 at 1:00 PM
Immune Design Corp. (IMDZ) Short Interest Down 65.5% in OctoberImmune Design Corp. (IMDZ) Short Interest Down 65.5% in October
www.americanbankingnews.com - November 13 at 3:34 AM
Immune Design Corp. (IMDZ) Expected to Post Earnings of -$0.39 Per ShareImmune Design Corp. (IMDZ) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - November 11 at 3:26 PM
Immune Design Corp. (IMDZ) Lowered to Hold at Zacks Investment ResearchImmune Design Corp. (IMDZ) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 10 at 12:16 PM
Immune Design Corp. (IMDZ) Director Lewis W. Coleman Acquires 50,000 SharesImmune Design Corp. (IMDZ) Director Lewis W. Coleman Acquires 50,000 Shares
www.americanbankingnews.com - November 6 at 12:30 PM
Immune Design Corp. (IMDZ) Stock Rating Upgraded by Zacks Investment ResearchImmune Design Corp. (IMDZ) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 6 at 12:16 PM
Brokers Set Expectations for Immune Design Corp.s FY2017 Earnings (IMDZ)Brokers Set Expectations for Immune Design Corp.'s FY2017 Earnings (IMDZ)
www.americanbankingnews.com - November 6 at 4:56 AM
Jefferies Group Comments on Immune Design Corp.s FY2017 Earnings (IMDZ)Jefferies Group Comments on Immune Design Corp.'s FY2017 Earnings (IMDZ)
www.americanbankingnews.com - November 6 at 4:56 AM
Immune Design Corp. :IMDZ-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Immune Design Corp. :IMDZ-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 2:12 AM
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3
finance.yahoo.com - November 3 at 9:35 AM
Edited Transcript of IMDZ earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of IMDZ earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 9:35 AM
Immune Design Corp. (IMDZ) Receives Average Recommendation of "Buy" from AnalystsImmune Design Corp. (IMDZ) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 3 at 5:46 AM
ETFs with exposure to Immune Design Corp. : November 1, 2017ETFs with exposure to Immune Design Corp. : November 1, 2017
finance.yahoo.com - November 2 at 2:13 AM
Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 2 at 2:13 AM
Immune Design reports 3Q lossImmune Design reports 3Q loss
finance.yahoo.com - November 2 at 2:13 AM
Immune Design Corp. (IMDZ) Director Purchases $114,500.00 in StockImmune Design Corp. (IMDZ) Director Purchases $114,500.00 in Stock
www.americanbankingnews.com - November 1 at 8:52 PM
Immune Design Corp. (IMDZ) Releases  Earnings Results, Beats Estimates By $0.11 EPSImmune Design Corp. (IMDZ) Releases Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - November 1 at 8:34 PM
Immune Design Corp. (IMDZ) Major Shareholder Leo Guthart Acquires 2,439,000 SharesImmune Design Corp. (IMDZ) Major Shareholder Leo Guthart Acquires 2,439,000 Shares
www.americanbankingnews.com - October 31 at 8:28 PM
Whats in the Cards for Immune Design (IMDZ) in Q3 Earnings?What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
www.zacks.com - October 31 at 3:05 AM
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
finance.yahoo.com - October 30 at 10:03 PM
Immune Design Corp. (IMDZ) to Release Earnings on WednesdayImmune Design Corp. (IMDZ) to Release Earnings on Wednesday
www.americanbankingnews.com - October 30 at 1:50 PM
Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate UpdateImmune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update
finance.yahoo.com - October 28 at 6:58 AM
Options Traders Expect Huge Moves in Immune Design (IMDZ) StockOptions Traders Expect Huge Moves in Immune Design (IMDZ) Stock
finance.yahoo.com - October 28 at 6:58 AM
Immune Design Corp. (IMDZ) Director Purchases $10,992,100.00 in StockImmune Design Corp. (IMDZ) Director Purchases $10,992,100.00 in Stock
www.americanbankingnews.com - October 27 at 8:22 PM
Immune Design Corp. (IMDZ) Director Buys $106,500.00 in StockImmune Design Corp. (IMDZ) Director Buys $106,500.00 in Stock
www.americanbankingnews.com - October 26 at 8:33 PM
Immune Design prices $80M public offering of common stockImmune Design prices $80M public offering of common stock
seekingalpha.com - October 26 at 1:37 PM
Immune Design Prices $80.0 Million Public Offering of Common StockImmune Design Prices $80.0 Million Public Offering of Common Stock
finance.yahoo.com - October 25 at 6:24 AM
Immune Design Corp. (IMDZ) Major Shareholder Leo Guthart Buys 60,000 SharesImmune Design Corp. (IMDZ) Major Shareholder Leo Guthart Buys 60,000 Shares
www.americanbankingnews.com - October 24 at 7:18 PM
Immune Design Corp. (IMDZ) Expected to Post Quarterly Sales of $620,000.00Immune Design Corp. (IMDZ) Expected to Post Quarterly Sales of $620,000.00
www.americanbankingnews.com - October 24 at 5:48 AM
Immune Design (IMDZ) Announces 16M Share Common OfferingImmune Design (IMDZ) Announces 16M Share Common Offering
www.streetinsider.com - October 24 at 12:33 AM
Immune Design Announces Proposed Public Offering of Common StockImmune Design Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 23 at 7:31 PM
ValuEngine Downgrades Immune Design Corp. (IMDZ) to Strong SellValuEngine Downgrades Immune Design Corp. (IMDZ) to Strong Sell
www.americanbankingnews.com - October 21 at 10:40 AM
ETFs with exposure to Immune Design Corp. : October 20, 2017ETFs with exposure to Immune Design Corp. : October 20, 2017
finance.yahoo.com - October 21 at 2:11 AM
Immune Design Corp. to Post FY2018 Earnings of ($1.99) Per Share, Leerink Swann Forecasts (IMDZ)Immune Design Corp. to Post FY2018 Earnings of ($1.99) Per Share, Leerink Swann Forecasts (IMDZ)
www.americanbankingnews.com - October 20 at 5:26 PM
Immune Design Corp. (IMDZ) Major Shareholder Acquires $60,900.00 in StockImmune Design Corp. (IMDZ) Major Shareholder Acquires $60,900.00 in Stock
www.americanbankingnews.com - October 20 at 1:16 PM
Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s LymphomaImmune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma
finance.yahoo.com - October 20 at 12:07 AM
Is Immune Design Corp (IMDZ) Undervalued?Is Immune Design Corp (IMDZ) Undervalued?
finance.yahoo.com - October 20 at 12:07 AM
Relative Strength Alert For Immune DesignRelative Strength Alert For Immune Design
www.thestreet.com - October 19 at 5:02 AM
Immune Design continues freefall, down 20%Immune Design continues freefall, down 20%
seekingalpha.com - October 19 at 5:02 AM
Immune Design Corp. (IMDZ) Downgraded by Wells Fargo & CompanyImmune Design Corp. (IMDZ) Downgraded by Wells Fargo & Company
www.americanbankingnews.com - October 17 at 1:34 PM
Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma PatientsImmune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
finance.yahoo.com - October 16 at 8:37 PM
ETFs with exposure to Immune Design Corp. : October 9, 2017ETFs with exposure to Immune Design Corp. : October 9, 2017
finance.yahoo.com - October 9 at 7:52 PM

SEC Filings

Immune Design (NASDAQ:IMDZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immune Design (NASDAQ:IMDZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immune Design (NASDAQ IMDZ) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.